-

Organigram Holdings Inc. Files Preliminary Base Shelf Prospectus

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licenced producer of cannabis, announced today that it has filed a preliminary short form base shelf prospectus (the “Base Shelf Prospectus”) with the securities commissions in each of the provinces and territories of Canada. A corresponding shelf registration statement on Form F-10 (the “Registration Statement”) has been filed with the United States Securities and Exchange Commission but is not yet effective.

The Base Shelf Prospectus, when made final and effective, will allow Organigram to qualify the distribution of up to C$500,000,000 of common shares, debt securities, subscription receipts, warrants, and units during the 25-month period that the Base Shelf Prospectus remains effective. The specific terms of any future offering of securities will ‎be established in a prospectus supplement filed with the applicable Canadian and US regulatory authorities. The Base Shelf Prospectus when final and effective, will provide flexibility for financing options to pursue the Company’s objectives.

A copy of the Base Shelf Prospectus can be found on SEDAR+ at www.sedarplus.ca and a copy of the Registration Statement can be found on EDGAR at www.sec.gov.

No offer to buy any securities of the Company can be accepted until the Registration Statement has become effective.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include: Organigram Inc. and Laurentian Organic Inc., licensed producers of cannabis and cannabis-derived products in Canada, and The Edibles and Infusions Corporation, a licensed manufacturer of cannabis-infused edibles in Canada.

Organigram is focused on producing high-quality cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). In addition, there can be no assurance that Organigram will obtain a receipt qualifying a final short form base shelf prospectus, that any prospectus supplements will be filed, that any financings will be completed under the short form base shelf prospectus, and that the objectives sought from any financings will be fulfilled. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contacts

For Investor Relations enquiries, please contact:
Max Schwartz
Director of Investor Relations
investors@organigram.ca
Organigram

For Media enquiries, please contact:
Megan McCrae
Senior Vice President of Marketing and Communications
megan.mccrae@organigram.ca
Organigram

Organigram Holdings Inc.

NASDAQ:OGI

Release Versions

Contacts

For Investor Relations enquiries, please contact:
Max Schwartz
Director of Investor Relations
investors@organigram.ca
Organigram

For Media enquiries, please contact:
Megan McCrae
Senior Vice President of Marketing and Communications
megan.mccrae@organigram.ca
Organigram

More News From Organigram Holdings Inc.

Organigram Extends Innovation Investment with Phylos

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share1, today announced the expansion of its innovation investment in Phylos Bioscience Inc. (“Phylos”), securing Organigram’s position as a leader in seed-based cannabis genetics. Through an amended loan and product agreement, Organigram gains priority access to Phylos’ autoflower genetics pipeline, including preferential economic terms and long-ter...

Organigram Reports Record Fourth Quarter and Fiscal 2025 Results

TORONTO--(BUSINESS WIRE)--Organigram Global Inc (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 recreational cannabis company by market share2, is pleased to announce record results for the fourth quarter and twelve months ended September 30, 2025 (“Q4 Fiscal 2025” or "Fiscal 2025"). All financial information in this press release is expressed in Canadian dollars ("$"). FOURTH QUARTER 2025 FINANCIAL HIGHLIGHTS Gross Revenue: $123.3 million (+76% year-over-year). Net Reven...

Organigram to Report Fourth Quarter Fiscal 2025 Results on December 16, 2025

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, announced today it will report earnings results for its fourth quarter fiscal 2025 ended September 30, 2025, on Tuesday, December 16, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, December 16, 2025 Time: 8:00 am Eastern Time To register for the conference cal...
Back to Newsroom